ARCH Venture Management, LLC - Q1 2022 holdings

$700 Million is the total value of ARCH Venture Management, LLC's 8 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 33.3% .

 Value Shares↓ Weighting
KRTX  KARUNA THERAPEUTICS, INC.$369,323,000
-3.2%
2,912,8720.0%52.78%
+30.7%
 EQRX, INC.$150,065,000
-39.4%
36,335,3750.0%21.44%
-18.2%
 ERASCA, INC.$95,078,000
-44.8%
11,055,5540.0%13.59%
-25.4%
VERV  VERVE THERAPEUTICS, INC.$57,251,000
-38.1%
2,508,8090.0%8.18%
-16.4%
OMIC  SINGULAR GENOMICS SYSTEMS, INC.$23,971,000
-45.4%
3,798,9260.0%3.43%
-26.3%
RUBY  RUBIUS THERAPEUTICS, INC.$1,928,000
-43.1%
349,9080.0%0.28%
-22.9%
MTCR NewMETACRINE, INC.$1,793,0002,940,503
+100.0%
0.26%
ZY  ZYMERGEN INC.$345,000
-56.7%
119,2050.0%0.05%
-41.7%
PULM ExitPULMATRIX, INC.$0-43,639
-100.0%
-0.00%
NTRA ExitNATERA, INC.$0-32,098
-100.0%
-0.32%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2022-05-27
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
RUBIUS THERAPEUTICS, INC.12Q3 202265.5%
EQRX, INC.8Q3 202352.4%
ERASCA, INC.8Q3 202318.8%
VERVE THERAPEUTICS, INC.8Q3 202323.3%
CHIASMA INC8Q3 202025.7%
SINGULAR GENOMICS SYSTEMS, INC.8Q3 20234.6%
KURA ONCOLOGY INC7Q2 202027.6%
KARUNA THERAPEUTICS, INC.6Q1 202352.8%
DENALI THERAPEUTICS, INC.6Q3 202328.6%
SYROS PHARMACEUTICALS INC5Q3 202043.8%

View ARCH Venture Management, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-09
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-10
13F-HR2022-08-15
13F-HR/A2022-05-27
13F-HR2022-05-13
13F-HR2022-02-14

View ARCH Venture Management, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export ARCH Venture Management, LLC's holdings